Active, not recruitingPhase 3NCT04944979
Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)
Studying Primary immunodeficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Kedrion S.p.A.
- Principal Investigator
- Chiara AzzariAzienda Ospedaliero-Universitaria Ospedale Pediatrico Meyer - Italy
- Intervention
- Kedrion IVIG 10%(biological)
- Enrollment
- 30 enrolled
- Eligibility
- 2-16 years · All sexes
- Timeline
- 2021 – 2026
Study locations (20)
- Benioff Children's Hospital - Mission Bay, San Francisco, California, United States
- IMMUNOe Health and Research Centers, Centennial, Colorado, United States
- Johns Hopkins All Children's Hospital, St. Petersburg, Florida, United States
- Velocity Clinical Research - MedPharmics - Lafayette, Lafayette, Louisiana, United States
- Louisiana State University Shreveport, Shreveport, Louisiana, United States
- Duke Children's Hospital & Health Center, Durham, North Carolina, United States
- Asthma and Allergy Center - Toledo, Toledo, Ohio, United States
- Vital Prospects Clinical Research Institute PC, Tulsa, Oklahoma, United States
- Dél-Pesti Centrumkórház - Országos Hematológiai És Infektológiai Intézet, Budapest, Hungary
- SST Spedali Civili di Brescia, Brescia, Italy
- Azienda Ospedaliero-Universitaria - Ospedale Pediatrico Meyer, Florence, Italy
- I.R.C.C.S. Istituto Giannina Gaslini, Genova, Italy
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinic, Milan, Italy
- Azienda Ospedaliera Universitaria "Federico II", Naples, Italy
- Fondazione Policlinico Tor Vergata, Roma, Italy
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04944979 on ClinicalTrials.govOther trials for Primary immunodeficiency
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE4NCT07076446An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)CSL Behring
- RECRUITINGPHASE1, PHASE2NCT06839456Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCTChildren's Hospital of Philadelphia
- RECRUITINGNCT06565078A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary ImmunodeficiencyTakeda
- RECRUITINGNANCT07261891Ex Vivo Evaluation of JAK-inhibitor and Gene Therapeutical Approach in JAK-STAT Related Disordersprof. dr. Rik Schrijvers
- ENROLLING BY INVITATIONNCT06144229Real-world Effectiveness of HPV Vaccine in Women Living With HIV and Its Impact on Cervical Cancer Screening AccuraciesUniversity of California, Los Angeles
- ACTIVE NOT RECRUITINGPHASE2NCT06549114Leniolisib for Immune Dysregulation in PIDsPharming Technologies B.V.
- RECRUITINGNANCT06659588Study of Populations at Risk of Developing Chronic Hepatitis Linked to Chronic Enteric Virus Infection in Patients With Primary Immunodeficiency and Secondary Humoral DeficiencyAssistance Publique - Hôpitaux de Paris
- RECRUITINGNANCT07004803Virtual Reality on Pain and Fear Levels of Children With Primary ImmunodeficiencyDr. Hatice Dönmez